Back to today’s briefing

Story perspectives

Emma Walmsley Exits GSK, Luke Miels Steps Up as CEO

9/29/2025

50 4 Full Breakdown

Summary

Walmsley Exits GSK

Emma Walmsley will step down as GlaxoSmithKline (GSK) CEO December 31, 2025; Luke Miels, GSK's chief commercial officer, will become CEO January 1, 2026.
Analysts express mixed views about Miels' capability, with concerns about innovation and shareholder returns.
GSK plans to invest $30 billion in U.S. operations over five years, including Pennsylvania factory.
Walmsley will assist through September 30, 2026.

Summary

Miels Takes GSK Helm

GSK shares rose 3.4% to 1,533p, making it the FTSE 100's top gainer, despite a near 6% decline since Walmsley's appointment.
Luke Miels will become CEO on January 1, 2026, succeeding Walmsley's nine-year tenure.
Walmsley led on innovative medicines, including vaccines, but investor confidence cooled amid competition and patent expirations, with scrutiny of vaccine strategy and HIV treatments losses.

1 of 2

Walmsley Exits GSK

Emma Walmsley will step down as GlaxoSmithKline (GSK) CEO December 31, 2025; Luke Miels, GSK's chief commercial officer, will become CEO January 1, 2026.
Analysts express mixed views about Miels' capability, with concerns about innovation and shareholder returns.
GSK plans to invest $30 billion in U.S. operations over five years, including Pennsylvania factory.
Walmsley will assist through September 30, 2026.

1 / 2